Bruker Announces Successful Installation of 1.2 GHz Avance® NMR Spectrometer at the Korea Basic Science Institute (KBSI)
Bruker has successfully installed Asia's first 1.2 GHz Avance® Nuclear Magnetic Resonance (NMR) spectrometer at the Korea Basic Science Institute (KBSI). This ultra-high field NMR system sets a new benchmark for molecular, cell biology, and disease research in the Asia-Pacific region. The installation enhances KBSI's capabilities in biomolecular structure analysis and drug development, enabling researchers to observe functional molecular dynamics and structural rearrangements in real time.
The 1.2 GHz NMR spectrometer will support various research applications, including the study of intrinsically disordered proteins, drug-target binding mechanisms, and the development of diagnostic methods for infectious diseases. With this installation, there are now 22 GHz-class NMR spectrometers worldwide, highlighting the growing importance of advanced NMR technology in scientific research.
Bruker ha installato con successo il primo spettrometro di Risonanza Magnetica Nucleare (NMR) Avance® da 1,2 GHz in Asia presso il Korea Basic Science Institute (KBSI). Questo sistema NMR ultra-alto campo rappresenta un nuovo punto di riferimento per la ricerca in biologia molecolare, cellulare e sulle malattie nella regione Asia-Pacifico. L'installazione potenzia le capacità del KBSI nell'analisi della struttura biomolecolare e nello sviluppo di farmaci, consentendo ai ricercatori di osservare in tempo reale la dinamica molecolare funzionale e i riarrangiamenti strutturali.
Lo spettrometro NMR da 1,2 GHz sosterrà varie applicazioni di ricerca, inclusi lo studio di proteine intrinsecamente disordinate, i meccanismi di legame farmaco-target e lo sviluppo di metodi diagnostici per le malattie infettive. Con questa installazione, ora ci sono 22 spettrometri NMR di classe GHz in tutto il mondo, evidenziando l'importanza crescente della tecnologia NMR avanzata nella ricerca scientifica.
Bruker ha instalado con éxito el primer espectrómetro de Resonancia Magnética Nuclear (NMR) Avance® de 1,2 GHz en Asia en el Korea Basic Science Institute (KBSI). Este sistema NMR de ultra-alto campo establece un nuevo estándar para la investigación en biología molecular, celular y de enfermedades en la región Asia-Pacífico. La instalación mejora las capacidades del KBSI en análisis de estructuras biomoleculares y desarrollo de fármacos, permitiendo a los investigadores observar en tiempo real la dinámica molecular funcional y los reordenamientos estructurales.
El espectrómetro NMR de 1,2 GHz apoyará diversas aplicaciones de investigación, incluyendo el estudio de proteínas intrínsecamente desordenadas, mecanismos de unión fármaco-objetivo y el desarrollo de métodos de diagnóstico para enfermedades infecciosas. Con esta instalación, ya hay 22 espectrómetros NMR de clase GHz en todo el mundo, destacando la creciente importancia de la tecnología NMR avanzada en la investigación científica.
브루커는 한국기초과학지원센터(KBSI)에 아시아 최초의 1.2 GHz Avance® 핵자기공명(NMR) 분광기를 성공적으로 설치했습니다. 이 초고장 NMR 시스템은 아시아 태평양 지역에서 분자 생물학, 세포 생물학 및 질병 연구의 새로운 기준을 설정합니다. 설치는 KBSI의 생체분자 구조 분석 및 약물 개발 역량을 강화하여 연구자들이 기능적 분자 역학과 구조적 재배치를 실시간으로 관찰할 수 있도록 합니다.
1.2 GHz NMR 분광기는 내재적으로 무질서한 단백질, 약물-표적 결합 메커니즘 및 감염병 진단 방법 개발 등 다양한 연구 응용을 지원할 것입니다. 이번 설치로 전 세계에 22개의 GHz급 NMR 분광기가 존재하게 되었으며, 이는 과학 연구에서 고급 NMR 기술의 중요성이 커지고 있음을 부각시킵니다.
Bruker a installé avec succès le premier spectromètre de Résonance Magnétique Nucléaire (RMN) Avance® de 1,2 GHz en Asie au Korea Basic Science Institute (KBSI). Ce système RMN ultra-haut champ établit une nouvelle référence pour la recherche en biologie moléculaire, biologie cellulaire et recherche sur les maladies dans la région Asie-Pacifique. L'installation renforce les capacités du KBSI en analyse de structures biomoléculaires et développement de médicaments, permettant aux chercheurs d'observer en temps réel la dynamique moléculaire fonctionnelle et les réarrangements structuraux.
Le spectromètre RMN de 1,2 GHz soutiendra diverses applications de recherche, y compris l'étude des protéines intrinséquement désordonnées, les mécanismes de liaison médicament-cible et le développement de méthodes de diagnostic pour les maladies infectieuses. Avec cette installation, il y a maintenant 22 spectromètres RMN de classe GHz dans le monde, soulignant l'importance croissante de la technologie RMN avancée dans la recherche scientifique.
Bruker hat erfolgreich das erste 1,2 GHz Avance® Kernspinresonanz (NMR) Spektrometer in Asien am Korea Basic Science Institute (KBSI) installiert. Dieses ultra-hochfeld NMR-System setzt einen neuen Maßstab für die molekulare Biologie, Zellbiologie und Krankheitsforschung in der Asien-Pazifik-Region. Die Installation verbessert die Fähigkeiten des KBSI in der Analyse biomolekularer Strukturen und der Medikamentenentwicklung und ermöglicht es den Forschern, funktionale molekulare Dynamiken und strukturelle Umstellungen in Echtzeit zu beobachten.
Das 1,2 GHz NMR Spektrometer wird diverse Forschungsanwendungen unterstützen, einschließlich der Untersuchung von intrinsisch ungeordneten Proteinen, den Bindungsmechanismen von Arzneimitteln und Zielen sowie der Entwicklung von Diagnosetechniken für Infektionskrankheiten. Mit dieser Installation gibt es jetzt 22 GHz-Klasse NMR-Spektrometer weltweit, was die wachsende Bedeutung fortschrittlicher NMR-Technologie in der wissenschaftlichen Forschung hervorhebt.
- Installation of Asia's first 1.2 GHz Avance® NMR spectrometer at KBSI
- Enhanced capabilities in biomolecular structure analysis and drug development
- Improved sensitivity and resolution for observing molecular dynamics
- Potential advancements in medical research and materials science
- Growing global adoption of GHz-class NMR spectrometers (22 installed worldwide)
- None.
The installation of Asia's first 1.2 GHz Avance® NMR spectrometer at KBSI marks a significant leap in research capabilities. This ultra-high field NMR system offers unprecedented resolution and sensitivity, enabling researchers to observe molecular dynamics in real-time. The technology's ability to elucidate complex biological processes, such as protein-ligand interactions and intrinsically disordered proteins, is important for understanding disease mechanisms and drug development.
With 22 GHz-class NMR spectrometers now installed worldwide, including two in Asia-Pacific, we're seeing a growing trend in adopting cutting-edge research infrastructure. This installation not only enhances KBSI's research capabilities but also positions the institute as a leader in biomolecular structure analysis in the region.
The 1.2 GHz NMR spectrometer at KBSI opens new avenues for biomedical research. Its applications in mechanistic understanding of drug-target binding and molecular communication are particularly promising for drug discovery and development. The ability to study intrinsically disordered proteins with such high resolution could lead to breakthroughs in understanding neurodegenerative diseases.
Moreover, the spectrometer's potential in biomedical multiomics, bioimaging and diagnostic method development for infectious diseases broadens its impact across various medical fields. This technology could accelerate research in personalized medicine and enhance our understanding of complex biological systems, potentially leading to more effective treatments for a range of diseases.
Bruker 's successful installation of the 1.2 GHz NMR system at KBSI strengthens its position in the high-end scientific instruments market. As the 22nd GHz-class NMR spectrometer installed worldwide, it demonstrates growing market demand for ultra-high field NMR technology. This installation could spark increased interest from other research institutions in the Asia-Pacific region, potentially driving future sales for Bruker.
The timing of the installation, coinciding with the ICMRBS 2024 conference, provides Bruker with a prime opportunity for showcasing the technology to a relevant audience. The offered tour of the facility could generate significant buzz and potential leads. Long-term, this installation could lead to increased collaboration between Bruker and academic institutions, fostering innovation and potentially opening new revenue streams through joint research initiatives.
Asia’s first 1.2 GHz NMR system empowers researchers to advance scientific discoveries
1.2 GHz Avance® NMR system at Korea Basic Science Institute (KBSI)
This underscores KBSI’s unwavering commitment to innovation in research infrastructure, cementing its status as a world-class fundamental research institute. This cutting-edge 1.2 GHz NMR spectrometer further enhances KBSI’s capabilities in biomolecular structure analysis and drug development, pushing the boundaries of protein NMR research. Ultra-high field NMR provides excellent sensitivity and unprecedented resolution, enabling researchers to observe functional molecular dynamics and structural rearrangements in real time. Complementary to other structural biology technologies, GHz-class NMR allows KBSI to elucidate complex biological processes, such as protein-ligand interactions and the behavior of intrinsically disordered proteins, which are crucial for understanding disease mechanisms and developing new therapeutic strategies.
Dr. Hae-Kap Cheong, Manager of the UHF NMR system at KBSI, expressed his enthusiasm: “When using the 1.2 GHz instrument, the opportunities for small molecule research made me speechless. In particular, the structural elucidation of natural products will be greatly beneficial.”
Dr. Donghan Lee, Scientific Researcher at KBSI, adds: “As Richard Feynman said, ‘Everything that living things do can be understood in terms of the jiggling and wiggling of atoms.’ The function of biomolecules can be understood by their dynamic nature. In particular, the functional conformation of biomolecules may be hidden because of their dynamic nature. With the 1.2 GHz instrument, the detection of these conformations enables the unprecedented identification of functional conformations.”
KBSI is dedicated to advancing scientific research through state-of-the-art technology and innovative research facilities. As a platform for global basic research, KBSI connects research facilities, equipment, and researchers, driving the future of science and technology in the
Dr. Kyoung-Seok Ryu, Director of the Biopharmaceutical Research Center at KBSI, added: “The application of the 1.2 GHz instrument includes mechanistic understanding, in particular, the mode-of-action of drug-target binding and molecular communication. Furthermore, studying intrinsically disordered or partially disordered proteins with the 1.2 GHz NMR instrument can elucidate the functional mechanisms underlying neurodegeneration.”
KBSI will utilize the 1.2 GHz spectrometer for a diverse range of research applications, including the study of biomolecular structures and the development of new drugs. This ultra-high field NMR instrument will support other KBSI research in biomedical multiomics, bioimaging, and the development of diagnostic methods for infectious diseases. The broader benefits of this research will extend to advancements in medical research, materials science, and other critical fields.
Dr. Falko Busse, President of Bruker BioSpin, commented: “We are thrilled to see the 1.2 GHz NMR become a key part of KBSI’s research infrastructure. Grateful for the trust from KBSI, we look forward to the scientific advancements that will emerge. We are pleased to offer a tour of the 1.2 GHz NMR at KBSI during the International Conference on Magnetic Resonance in Biological Systems.”
Interested researchers can book the tour at Bruker Booth A1 at ICMRBS for Friday, August 23, providing a unique opportunity to explore the advanced capabilities of this revolutionary instrument.
With the installation at KBSI, there are now 22 GHz-class NMR spectrometers installed worldwide, including two in the
About Bruker Corporation – Leader of the Post-Genomic Era (Nasdaq: BRKR)
Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s high performance scientific instruments and high value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with our customers, Bruker is enabling innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-gen semiconductor metrology in support of AI. Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics. For more information, please visit www.bruker.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240813101964/en/
Investor Contact:
Joe Kostka
Associate Director - Investor Relations
Bruker Corporation
T: +1 (978) 313-5800
E: Investor.Relations@bruker.com
Media Contact:
Markus Ziegler
Sr. Director and Head of Group Marketing
Bruker BioSpin
T: +49 172 3733531
E: pr@bruker.com
Source: Bruker Corporation
FAQ
What is the significance of Bruker's 1.2 GHz NMR installation at KBSI?
How many GHz-class NMR spectrometers are now installed worldwide after KBSI's installation?
What research applications will KBSI's 1.2 GHz NMR spectrometer support?
When was the Bruker 1.2 GHz NMR spectrometer installed at KBSI?
